Tuğçe Şahin Özdemirel(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ATATÜRK GÖĞÜS HASTALIKLARI VE GÖĞÜS CERRAHİSİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-1596-0082
Özlem Ertan(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ATATÜRK GÖĞÜS HASTALIKLARI VE GÖĞÜS CERRAHİSİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-1530-6999
Berna Akıncı Özyürek(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ATATÜRK GÖĞÜS HASTALIKLARI VE GÖĞÜS CERRAHİSİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-0206-7615
In this case, we aimed to present our patient with the diagnosis of MS who was followed up for severe Covid 19 pneumonia and for whom EzPAP® positive airway pressure therapy system was used for treatment.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Abstract In patients with multiple sclerosis (MS) respiratory muscle weakness and related development of respiratory failure are important causes of mortality.
📊
Key Findings & Data:Complications such as atelectasis and susceptibility to respiratory infections are common in these patients.
💡
Conclusion & Impact:In this case, we aimed to present our patient with the diagnosis of MS who was followed up for severe Covid 19 pneumonia and for whom EzPAP® positive airway pressure therapy system was used for treatment.
Abstract In patients with multiple sclerosis (MS) respiratory muscle weakness and related development of respiratory failure are important causes of mortality. Complications such as atelectasis and susceptibility to respiratory infections are common in these patients. In cases of atelectasis and hypoxemia that develop due to the weakness of inspiratory muscles, the use of EzPAP® positive airway pressure therapy system should also be kept in mind, in addition to nasal oxygen and NIMV treatment options. In this case, we aimed to present our patient with the diagnosis of MS who was followed up for severe Covid 19 pneumonia and for whom EzPAP® positive airway pressure therapy system was used for treatment.
Akkurt, E. S., Özdemirel, T. Ş., Ertan, Ö., Özyürek, B. A. (2022). The use of ezpap in patients with Covid-19 pneumonia and multiple sclerosis. Journal of Experimental and Clinical Medicine, Volume: 39 Issue: 2. https://ajindex.com/articles/1423079
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-1720.
Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526-33.
Adams RD, Victor M. Principles of Neurology. 7. edition, Mc GrawHill international editions;2021; 954-979.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention. Jama. 2020 Feb 24.(Online ahead of print)
Daniel BM, Tarnow JL. EzPAPTM: An alternative in lung expansion therapy (abstract). Respir Care 2001;46:1143.
Wiersgalla S. Effects of EzPAP postoperatively in coronary artery bypass graft patients (abstract). Respir Care 2002;47:1037.
Rieg AD, Stoppe C, Rossaint R, Coburn M, Hein M, Schalte G. [EzPAP(R) therapy of postoperative hypoxemia in the recovery room: Experiences with the new compact system of end-expiratory positive airway pressure]. Anaesthesist;2012, 61:867–874.
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606-16.
Brown TR, Kraft GH. Exercise and rehabilitation for individuals with multiple sclero- sis. Phys Med Rehabil Clin N Am 2005;16:513-55.5. McAlpine’s Multiple Sclerosis. Fourth edition. Ed: Alastair Compston. Churchill Livingstone Elsevier; 2006: 285-446
Gosselink R, Kovacs L, Ketelaer P, Carton H, Decramer M. Respiratory muscle weakness and respiratory muscle training in severely disabled Multiple Sclerosis patients. Arch Phys Med Rehabil.2000; 81(6): 747- 751.
Shefner JM, Parsons PE, Morrison RS. Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluationwww.uptodate.com Updated: Sep 01, 2015
Ward S, Chatwin M, Heather S. Randomised controlled trial of non-invasive ventilation (NİV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax 2005;60(12):1019.
Annane D, Chevrolet JC, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev 2000:CD001941
Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5(2):140.